TRENTON, NJ (May 14, 2015) — BioNJ, The Gateway to Health, is pleased with the passage of A2477, legislation that will allow greater Patient access to more affordable FDA-approved biologic medicines. Biological medicines are vital to the treatment of conditions such as cancer, diabetes, infectious diseases and a variety of immune disorders. BioNJ’s rallying cry is “Because Patients Can’t Wait,” and the passage of A2477 moves us one step closer to ensuring that Patients have access to medications and cures while guaranteeing transparency in the prescription process and protecting Patient safety as well as preserving the doctor-patient relationship.
With the passage of A2477, pharmacists are allowed to substitute biosimilar products provided the conditions set forth in the bill are met. Biological medicines are manufactured through biotechnology using living organisms and are much more complex than traditional, chemically-synthesized drugs. Because of their unique nature and the unique process required to develop them, it is impossible to produce an exact copy of an innovator biotech medication. Therefore, the safest approach is to require pharmacies to communicate the biological product dispensed to the attention of the prescriber.
“The passing of A2477 is an exemplary example of the New Jersey life sciences community coming together to ensure that innovative medical research is fostered, while interchangeable biological medicines are safely and more readily available to Patients in need of life-altering treatment,” said BioNJ’s President and CEO, Debbie Hart.
Thank you to Assemblywoman Pamela Lampitt, Assemblyman Herb Conaway, Jr., M.D., Assemblyman Daniel Benson, Assemblyman Angel Fuentes, Assemblywoman Shavonda Sumter, Assemblywoman Nancy Muñoz and Assemblywoman Nancy Pinkin for sponsoring the bill and for their continued support in finding cures for Patients. We also applaud the entire membership of the Assembly Health and Human Services Committee for their careful consideration of this bill.
BioNJ, The Gateway to Health, is a powerful network of 400 Member Investors representing research-based life sciences companies and stakeholders dedicated to propelling a vibrant ecosystem where Science is Supported, Companies are Created, Drugs are Developed and Patients are Paramount. Because Patients Can’t Wait, BioNJ is committed to the growth and prosperity of New Jersey’s life sciences ecosystem to help accelerate the discovery, development and commercialization of therapies and cures that save and improve lives and lessen the burden of illness and disease to society. As the industry’s voice in New Jersey, we fulfill our Mission to help companies help Patients by driving capital formation and fostering entrepreneurship, advocating for public policies that advance medical innovation, providing access to talent and education and offering a cost-saving array of critical commercial resources. For more information about BioNJ, please visit www.BioNJ.org.
Vice President, Communications and Marketing